Clinical trial

Spironolactone for Pulmonary Arterial Hypertension

NCT01712620

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2014-01-10

PhasePHASE2

Study timeline

Study start (actual)2014-01-10Date precision: day

Registry last updated2026-10-02

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Pulmonary Arterial Hypertensionunresolved

Interventions

SpironolactoneDRUG · verified · RxNorm: spironolactone

Sponsors & collaborators

National Institutes of Health Clinical Center (CC)lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)collaborator

University of Pennsylvaniacollaborator

University of Maryland, Baltimorecollaborator

Medstar Health Research Institutecollaborator

New England Medical Center, Tufts University School of Medicinecollaborator

Mapped research locations

BethesdaMaryland, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01712620 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.